Actively Recruiting
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-14
60
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to evaluate a new diagnostic imaging test called positron emission tomography (PET) using a radioactive form of iodine known as iodine-124 in adults with metastatic thyroid carcinoma. The study will assess how well this test measures the amount of radioactive iodine uptake in cancer lesions to help determine the best treatment approach, especially whether radioiodine therapy is suitable or if alternative therapies should be considered. Participants will receive injections of rhTSH on two consecutive days followed by an oral dose of iodine-124. They will undergo up to four whole-body PET/CT scans at specific times after the iodine-124 dose to collect detailed imaging data on tumor uptake and clearance. A subgroup of patients will receive additional doses of iodine-124 during their radioiodine therapy and undergo further PET scans to compare treatment effects. Throughout the study, participants will have measurable disease documented by imaging within six months prior. Researchers will monitor individual lesion responses over one year using PET imaging data. The study involves careful tracking of tumor behavior, safety monitoring, and follow-up assessments to determine the diagnostic test's value in guiding treatment decisions.
CONDITIONS
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 1 week
Participants receive 0.9 mg injections of rhTSH on two consecutive days, followed by a single oral dose of 124I. Up to four whole-body PET/CT scans are performed to assess lesion dosimetry based on 124I uptake and clearance.
Up to 4 PET/CT scanning visits and 2 injection visits
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
R
Ravinder Grewal, MD
S
Steven Larson, MD
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Audrey Mauguen, Ravinder K Grewal, Finn Augensen...
https://pubmed.ncbi.nlm.nih.gov/37171634